UBE2D1 and melanoma: To assess whether tumor-homing FNCs dissolve fibrin in the tumor microenvironment, a syngeneic allograft mouse model was constructed by implanting B16F10 mouse melanoma cells into mice, followed by daily intravenous injections of CLT-sFt-μP (15 mg/kg), sFt-μP (14.69 mg/kg), or CLT-sFt (7.5 mg/kg), for a total of four injections.